Canada Markets closed

Intellia Therapeutics, Inc. (NTLA)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
47.74+0.03 (+0.06%)
As of 04:00PM EDT. Market open.

Intellia Therapeutics, Inc.

40 Erie Street
Suite 130
Cambridge, MA 02139
United States
857 285 6200
https://www.intelliatx.com

Sector(s)Healthcare
IndustryBiotechnology
Full Time Employees485

Key Executives

NameTitlePayExercisedYear Born
Dr. John M. Leonard M.D.Pres, CEO & Director912.79k4.05M1957
Mr. Glenn G. Goddard CPAExec. VP, CFO & Treasurer562.45kN/A1971
Dr. Laura Sepp-LorenzinoExec. VP & Chief Scientific Officer609.38kN/A1961
Dr. David Lebwohl M.D.Exec. VP & Chief Medical Officer529.07kN/AN/A
Mr. Nessan Bermingham Ph.D.Founder & Member of Scientific Advisor BoardN/AN/A1973
Dr. Rachel E. Haurwitz Ph.D.Co-FounderN/AN/A1986
Dr. Andrew MayFounder and Member of Scientific Advisor BoardN/AN/AN/A
Dr. Jennifer A. Doudna Ph.D.Founder & Member of Scientific Advisor BoardN/AN/A1964
Dr. Derrick J. RossiFounder & Member of Scientific Advisor BoardN/AN/AN/A
Dr. Rodolphe Barrangou M.B.A., Ph.D.Founder & Member of Scientific Advisor BoardN/AN/AN/A
Amounts are as of December 31, 2020 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Intellia Therapeutics, Inc., a genome editing company, focuses on the development of therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; and NTLA-2002 for the treatment of hereditary angioedema, as well as other liver-focused programs comprising hemophilia A and hemophilia B, hyperoxaluria Type 1, and alpha-1 antitrypsin deficiency. Its ex vivo pipeline includes NTLA-5001 for the treatment of acute myeloid leukemia; and proprietary programs focused on developing engineered cell therapies to treat various oncological and autoimmune disorders. In addition, it offers tools comprising of Clustered, Regularly Interspaced Short Palindromic Repeats/CRISPR associated 9 (CRISPR/Cas9) system. Intellia Therapeutics, Inc. has license and collaboration agreements with Novartis Institutes for BioMedical Research, Inc. to engineer hematopoietic stem cells for the treatment of sickle cell disease; Regeneron Pharmaceuticals, Inc. to co-develop potential products for the treatment of hemophilia A and hemophilia B; Ospedale San Raffaele; and a strategic collaboration with SparingVision SAS to develop novel genomic medicines utilizing CRISPR/Cas9 technology for the treatment of ocular diseases. The company was formerly known as AZRN, Inc. Intellia Therapeutics, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.

Corporate Governance

Intellia Therapeutics, Inc.’s ISS Governance QualityScore as of May 1, 2022 is 8. The pillar scores are Audit: 6; Board: 8; Shareholder Rights: 8; Compensation: 9.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.